Oesophagus, stomach cancer Cancer Oesophagus, stomach
Conditions
Interventions
Patients are randomised to one of two chemotherapy regimens:
1. ECF Regimen: Multi-drug chemotherapy with epirubicin, cisplatin and 5-fluorouracil (FEC). Epirubicin and cisplatin repeated every 3 week
Sponsors
Cancer Research UK (CRUK) (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Histologically verified locally advanced or metastatic adenocarcinoma or undifferentiated carcinoma of the oesophagus or stomach 2. Bi-dimensionally measurable disease as assessed by Computed Tomography (CT), Magnetic Resonance Imaging (MRI) or radiography: evaluable disease; non-evaluable disease 3. No prior chemotherapy or radiotherapy 4. Adequate renal and hepatic function 5. Projected life expectancy of at least 3 months 6. No history of other malignant disease other than adequately treated non-melanotic skin cancer or in-situ carcinoma of the uterine cervix 7. No contraindications to treatment protocols
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed